SFX-01 Positive RNS2 Mar 2016 10:35
Now approved fore patient testing
Quote:
"SFX-01 has been advanced through preclinical and Phase I clinical trials and is now ready for Phase II trials in two indications - breast cancer and subarachnoid haemorrhage ("SAH"). The IPO on AIM on 21 October 2015, which raised £7 million before expenses, will provide the funding to complete Phase II trials in both indications."